MAPT and Alzheimer disease: Table 2 outlines the participants demographics, their classification as positive or negative for amyloid (A+/–), tau (T+/–), and neurodegeneration (N+/–) and the corresponding mean CSF concentrations of the corresponding AD biomarkers for each group.